Climb Bio, Inc. (CLYM)Healthcare | Biotechnology | Wellesley Hills, United States | NasdaqGM
10.91 USD
+0.62
(6.025%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 11:36 a.m. EDT
The investment case for Climb Bio is currently defined by severe structural deterioration rather than opportunity. The company has suffered a catastrophic multi-year decline, dropping nearly 87% over the last four years, with the most recent annual performance showing another sharp drop of nearly 65%. This relentless downward trajectory suggests the market has thoroughly priced in the risks associated with the company's cash burn and lack of profitability, rendering any 'value' narrative moot. While the balance sheet appears robust on paper due to low debt, the massive negative free cash flow and negative returns on equity indicate an unsustainable operational model that is draining capital without generating returns. The recent news of a private placement and index inclusion highlights the company's struggle to raise capital and maintain relevance, yet these events cannot reverse the fundamental reality of a failing business model. With no dividend to provide income and a stock price that has been decimated over the long term, there is no margin of safety here. The short-term outlook remains bleak as the market continues to digest the poor results, making this a security to avoid entirely. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.094915 |
| MSTL | 0.146827 |
| AutoETS | 0.154820 |
| AutoARIMA | 0.160069 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 2.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.248 |
| Excess Kurtosis | -0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.549 |
| Market Cap | 626,629,568 |
| Forward P/E | -10.88 |
| Beta | -0.03 |
| Previous Name | Eliem Therapeutics, Inc. |
| Website | https://climbbio.com |
As of Oct. 10, 2026, 11:36 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts relative to calls. The put/call ratio is skewed toward hedging or betting on further declines, while call volume is sparse and concentrated in distant strikes, indicating a lack of immediate bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.6528497 |
| Address1 | 20 William Street |
| Address2 | Suite G50 |
| All Time High | 29.69 |
| All Time Low | 1.05 |
| Ask | 16.06 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 959,360 |
| Average Daily Volume3 Month | 1,345,104 |
| Average Volume | 1,345,104 |
| Average Volume10Days | 959,360 |
| Beta | -0.031 |
| Bid | 9.05 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 4.171 |
| City | Wellesley Hills |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.91 |
| Current Ratio | 31.452 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 10.975 |
| Day Low | 10.25 |
| Debt To Equity | 0.549 |
| Display Name | Climb Bio |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,573,000 |
| Earnings Timestamp Start | 1,794,573,000 |
| Ebitda | -64,628,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.883 |
| Enterprise Value | 444,820,544 |
| Eps Current Year | -0.776 |
| Eps Forward | -1.003 |
| Eps Trailing Twelve Months | -0.82 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.7818 |
| Fifty Day Average Change | -2.8718004 |
| Fifty Day Average Change Percent | -0.20837629 |
| Fifty Two Week Change Percent | 465.28497 |
| Fifty Two Week High | 18.33 |
| Fifty Two Week High Change | -7.42 |
| Fifty Two Week High Change Percent | -0.4048009 |
| Fifty Two Week Low | 1.635 |
| Fifty Two Week Low Change | 9.275 |
| Fifty Two Week Low Change Percent | 5.672783 |
| Fifty Two Week Range | 1.635 - 18.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,628,602,200,000 |
| Float Shares | 38,740,754 |
| Forward Eps | -1.003 |
| Forward P E | -10.877368 |
| Free Cashflow | -33,989,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 28 |
| Fullday Change | -0.059999466 |
| Fullday Change Percent | -0.5499493 |
| Fullday Price | 10.85 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00179 |
| Held Percent Institutions | 1.05622 |
| Implied Shares Outstanding | 57,436,255 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts. |
| Long Name | Climb Bio, Inc. |
| Market | us_market |
| Market Cap | 626,629,568 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_603195850 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-16 |
| Net Income To Common | -57,624,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 718,814,731 |
| Number Of Analyst Opinions | 14 |
| Open | 10.32 |
| Operating Cashflow | -52,699,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Phone | 866 857 2596 |
| Pre Market Change | -0.059999466 |
| Pre Market Change Percent | -0.5499493 |
| Pre Market Price | 10.85 |
| Pre Market Time | 1,792,138,438 |
| Prev Name | Eliem Therapeutics, Inc. |
| Previous Close | 10.29 |
| Price Eps Current Year | -14.059278 |
| Price Hint | 2 |
| Price To Book | 2.6156797 |
| Profit Margins | 0.0 |
| Quick Ratio | 30.86 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.13333 |
| Region | US |
| Regular Market Change | 0.62 |
| Regular Market Change Percent | 6.02527 |
| Regular Market Day High | 10.975 |
| Regular Market Day Low | 10.25 |
| Regular Market Day Range | 10.25 - 10.975 |
| Regular Market Open | 10.32 |
| Regular Market Previous Close | 10.29 |
| Regular Market Price | 10.91 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 515,484 |
| Return On Assets | -0.18452999 |
| Return On Equity | -0.27097 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 57,436,255 |
| Shares Percent Shares Out | 0.1692 |
| Shares Short | 9,718,558 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 7,300,939 |
| Short Name | Climb Bio, Inc. |
| Short Percent Of Float | 0.2386 |
| Short Ratio | 5.36 |
| Source Interval | 15 |
| State | MA |
| Symbol | CLYM |
| Target High Price | 40.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 27.57143 |
| Target Median Price | 26.5 |
| Total Cash | 183,123,008 |
| Total Cash Per Share | 3.188 |
| Total Debt | 1,314,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.82 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.053575 |
| Two Hundred Day Average Change | 0.8564253 |
| Two Hundred Day Average Change Percent | 0.085186146 |
| Type Disp | Equity |
| Volume | 515,484 |
| Website | https://climbbio.com |
| Zip | 2,481 |